Alkem Laboratories inks out-licensing deal with Stempeutics Research

09 Feb 2018 Evaluate

Alkem Laboratories has inked an out-licensing deal with Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), for Stempeucel product for osteoarthritis indication. The out licensing deal comprises of upfront payment, royalties and various regulatory & sales based milestones payments.

Under this agreement, Alkem will get the exclusive marketing rights for Stempeucel in India for Osteoarthritis with Stempeutics manufacturing & supplying the product to Alkem. The product is expected to be available in Indian market by 2020 after undergoing the phase 3 Clinical trial in India, which is expected to commence in 2018.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.



Alkem Laboratories Share Price

5689.30 77.65 (1.38%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×